N. Tung

发表

Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group

Andrew H. Beck, Jacqueline A. Hall, Sarah N. Dudgeon, 2020, npj Breast Cancer.

Counselling framework for moderate-penetrance cancer-susceptibility mutations

Mark E. Robson, Susan M. Domchek, Kenneth Offit, 2016, Nature Reviews Clinical Oncology.

Genetic testing for hereditary breast and ovarian cancer and the USPSTF recommendations

J. Garber, C. Isaacs, I. Bedrosian, 2019, The breast journal.

Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers

B. Karlan, P. Møller, J. Lubiński, 2014, Breast Cancer Research and Treatment.

Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers

W. Foulkes, L. Salmena, J. Lubiński, 2012, Breast Cancer Research.

Infertility, treatment of infertility, and the risk of breast cancer among women with BRCA1 and BRCA2 mutations: a case–control study

P. Møller, W. Foulkes, S. Manoukian, 2008, Cancer Causes & Control.

Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers

F. Couch, B. Karlan, J. Klijn, 2007, Breast Cancer Research and Treatment.

Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers

O. Olopade, B. Karlan, W. Foulkes, 2005, Cancer Causes & Control.

Evolutionary pathways in BRCA1-associated breast tumors.

M. Gönen, K. Polyak, S. Schnitt, 2012, Cancer discovery.

Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk

W. Chung, P. Hall, V. Pankratz, 2013, PLoS genetics.

Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer.

Z. Szallasi, E. Winer, A. Eklund, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers.

O. Olopade, W. Foulkes, B. Weber, 2005, Gynecologic oncology.

Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation.

B. Karlan, P. Møller, W. Foulkes, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes

Jane E. Carpenter, Jaana M. Hartikainen, W. Chung, 2019, Nature Genetics.

Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features

D. Sgroi, S. Schnitt, R. Gelman, 2010, Breast Cancer Research.

Identification of six new susceptibility loci for invasive epithelial ovarian cancer

Yurii B. Shvetsov, Simon G. Coetzee, A. Whittemore, 2015, Nature Genetics.

Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer

Lara E Sucheston-Campbell, Simon G. Coetzee, Lara E. Sucheston-Campbell, 2017, Nature Genetics.

OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

Wei Li, B. Xu, M. Robson, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer.

B. Xu, M. Robson, N. Tung, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Germline E-cadherin mutations in familial lobular breast cancer

P. Miron, D. Huntsman, J. Senz, 2007, Journal of Medical Genetics.

Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothe

Carsten Denkert, Fred Hirsch, Benjamin Solomon, 2017, Advances in anatomic pathology.

Oophorectomy after Menopause and the Risk of Breast Cancer in BRCA1 and BRCA2 Mutation Carriers

B. Karlan, W. Foulkes, J. Lubiński, 2012, Cancer Epidemiology, Biomarkers & Prevention.

A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor–negative breast cancer in the general population

Christiana Kartsonaki, Mads Thomassen, Julian Peto, 2010, Nature Genetics.

Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers

Daniel L Gillen, Susan L Neuhausen, Fergus Couch, 2009, Breast Cancer Research.

Genetic Variation in IGF2 and HTRA1 and Breast Cancer Risk among BRCA1 and BRCA2 Carriers

F. Couch, O. Olopade, T. Rebbeck, 2011, Cancer Epidemiology, Biomarkers & Prevention.

Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers.

F. Couch, T. Rebbeck, R. Eeles, 2007, Clinical breast cancer.

Loss of BRCA1 leads to an increase in epidermal growth factor receptor expression in mammary epithelial cells, and epidermal growth factor receptor inhibition prevents estrogen receptor-negative cancers in BRCA1-mutant mice

Hai Hu, S. Troyan, N. Tung, 2011, Breast Cancer Research.

Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers

B. Karlan, P. Møller, W. Foulkes, 2018, JAMA oncology.

Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials

Jacqueline A. Hall, Sarah N. Dudgeon, A. Gown, 2020, npj Breast Cancer.

Fine-mapping of 150 breast cancer risk regions identifies 178 high confidence target genes

Jack A. Taylor, W. Chung, S. Cross, 2019, bioRxiv.

Altered proliferation and differentiation properties of primary mammary epithelial cells from BRCA1 mutation carriers.

Bernard T. Lee, S. Troyan, N. Tung, 2009, Cancer research.

Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study.

D. Fishman, B. Karlan, P. Møller, 2007, The Lancet. Oncology.

Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.

F. Couch, O. Olopade, J. Klijn, 2002, Journal of the National Cancer Institute.

Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study

C. Isaacs, S. Neuhausen, N. Tung, 2001, The Lancet.

What is the optimal endocrine therapy for postmenopausal women with hormone receptor-positive early breast cancer?

N. Tung, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer.

E. Winer, R. Gelman, P. Goss, 2010 .

Polygenic Risk Modelling for Prediction of Epithelial Ovarian Cancer Risk

A. Whittemore, W. Chung, L. Kiemeney, 2020, medRxiv.

Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline.

M. Somerfield, C. Isaacs, M. Robson, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Refined histopathological predictors of BRCA1 and BRCA2mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia

Jane E. Carpenter, Jaana M. Hartikainen, A. Whittemore, 2014, Breast Cancer Research.

Title: Evolutionary pathways in BRCA1-associated breast tumors

M. Gönen, K. Polyak, S. Schnitt, 2012 .

Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation.

F. Couch, O. Olopade, B. Karlan, 2006, JAMA.

Frequency of triple-negative breast cancer in BRCA1 mutation carriers: comparison between common Ashkenazi Jewish and other mutations.

J. Garber, N. Tung, S. Domchek, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Family history of cancer and cancer risks in women with BRCA1 or BRCA2 mutations.

W. Foulkes, J. Lubiński, S. Neuhausen, 2010, Journal of the National Cancer Institute.

Bilateral Oophorectomy and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers

B. Karlan, P. Møller, W. Foulkes, 2017, Journal of the National Cancer Institute.

Implications of Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.

L. Carey, A. Wolff, N. Tung, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.

F. Couch, O. Olopade, J. Klijn, 2002, Journal of the National Cancer Institute.

Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer.

John Kidd, Judy E Garber, E. Winer, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Germline genetic testing in breast cancer: Rationale for the testing of all women diagnosed by the age of 60 years and for risk‐based testing of those older than 60 years

F. Couch, N. Tung, S. Yadav, 2020, Cancer.

Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers

Jinbo Chen, F. Couch, O. Olopade, 2014, Breast Cancer Research and Treatment.

Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation.

B. Karlan, P. Møller, W. Foulkes, 2018, Gynecologic oncology.

Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors.

E. Winer, J. Baselga, J. Garber, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Does Neoadjuvant Bevacizumab Increase Surgical Complications in Breast Surgery?

Barbara L. Smith, E. Winer, S. Troyan, 2011, Annals of Surgical Oncology.

The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers.

O. Olopade, W. Foulkes, B. Weber, 2005, Gynecologic oncology.

Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer

Andrew H. Beck, Jacqueline A. Hall, Sarah N. Dudgeon, 2020, npj Breast Cancer.

Tamoxifen and the risk of ovarian cancer in BRCA1 mutation carriers.

C. Isaacs, J. Lubiński, N. Tung, 2009, Gynecologic Oncology.

Phase II Trial of Veliparib and Temozolomide in Metastatic Breast Cancer Patients With and Without BRCA1/2mutations

E. Winer, R. Gelman, J. Garber, 2021 .

TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes.

E. Winer, L. Carey, J. Garber, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Retinoblastoma protein expression and its predictors in triple-negative breast cancer

G. Freeman, S. Schnitt, J. Garber, 2020, npj Breast Cancer.

Managing hereditary breast cancer risk in women with and without ovarian cancer.

J. Garber, N. Tung, M. L. Peters, 2017, Gynecologic oncology.

Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group.

P. Møller, W. Foulkes, C. Isaacs, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Factors influencing ovulation and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers

B. Karlan, P. Møller, S. Friedman, 2015, International journal of cancer.

Cancer variation associated with the position of the mutation in the BRCA2 gene

D. Horsman, B. Weber, J. Garber, 2004, Familial Cancer.

Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): Safety and efficacy.

E. Winer, R. Gelman, J. Garber, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Smoking and the risk of breast cancer in BRCA1 and BRCA2 carriers: an update

J. Klijn, P. Møller, W. Foulkes, 2009, Breast Cancer Research and Treatment.

The risks of breast and ovarian cancer associated with the Ashkenazi Jewish founder allele BRCA2 6174delT

W. Foulkes, S. Neuhausen, E. Friedman, 2021, Clinical genetics.

Challenges and Opportunities in Engaging Primary Care Providers in BRCA Testing: Results from the BFOR Study

N. Keating, K. Offit, K. Nathanson, 2021, Journal of General Internal Medicine.

Targeted BRCA1/2 population screening among Ashkenazi Jewish individuals using a web-enabled medical model: An observational cohort study.

B. Karlan, K. Offit, K. Nathanson, 2021, Genetics in medicine : official journal of the American College of Medical Genetics.

Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations

Annette Lee, W. Chung, R. Nussbaum, 2018, Human mutation.

Reply to K. Zaman et al.

N. Tung, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis

W. Foulkes, N. Tung, B. Rosen, 2014, BMJ : British Medical Journal.

Risk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriers

O. Olopade, W. Foulkes, N. Tung, 2011, Breast Cancer Research and Treatment.

Phase I trial of docetaxel, carboplatin, and gemcitabine as first-line therapy for patients with high-risk epithelial tumors of müllerian origin.

J. Niloff, A. Berkenblit, S. Cannistra, 2003, Gynecologic oncology.

Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with granulocyte colony stimulating factor as first-line therapy for patients with advanced epithelial ovarian cancer.

J. Niloff, R. Berkowitz, S. Cannistra, 2000, Gynecologic oncology.

Age at first full-term birth and breast cancer risk in BRCA1 and BRCA2 mutation carriers

W. Foulkes, J. Lubiński, S. Neuhausen, 2018, Breast Cancer Research and Treatment.

TBCRC 030: A phase II study of preoperative cisplatin vs. paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker.

C. Perou, E. Winer, L. Trippa, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Evaluation of TP53 Variants Detected on Peripheral Blood or Saliva Testing: Discerning Germline From Somatic TP53 Variants.

J. Garber, N. Tung, H. Rana, 2021, JCO precision oncology.

Germline Genetic Testing for Women With Breast Cancer: Shifting the Paradigm From Whom to Test to Whom NOT to Test.

N. Tung, N. Desai, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers

O. Olopade, W. Foulkes, N. Tung, 2011, British Journal of Cancer.

Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3

W. Chung, R. Nussbaum, F. Couch, 2016, Breast Cancer Research and Treatment.

Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).

W. Chung, F. Couch, B. Bonanni, 2020, JAMA oncology.

BRCA1 and BRCA2 pathogenic sequence variants in women of African origin or ancestry

Annette Lee, F. Couch, O. Olopade, 2019, Human mutation.

Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers

F. Couch, O. Olopade, T. Rebbeck, 2010, Breast Cancer Research and Treatment.

Young adult daughters of BRCA1/2 positive mothers: What do they know about hereditary cancer and how much do they worry?

A. Patenaude, J. Garber, N. Tung, 2013, Psycho-oncology.

Breast cancer risk after age 60 among BRCA1 and BRCA2 mutation carriers

Stephanie A Cohen, O. Olopade, B. Karlan, 2021, Breast Cancer Research and Treatment.

Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers

F. Couch, O. Olopade, B. Karlan, 2019, Breast Cancer Research and Treatment.

Oestrogen receptor status and survival in women with BRCA2-associated breast cancer

O. Olopade, W. Foulkes, N. Tung, 2019, British Journal of Cancer.

Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk

W. Chung, P. Hall, V. Pankratz, 2013, PLoS Genetics.

Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers

F. Couch, O. Olopade, J. Klijn, 2005, International journal of cancer.

Anthropometric Measures and Risk of Ovarian Cancer Among BRCA1 and BRCA2 Mutation Carriers

B. Karlan, W. Foulkes, J. Lubiński, 2012, Obesity.

Correction: Common Genetic Variants and Modification of Penetrance of BRCA2-Associated Breast Cancer

M. Daly, D. Altshuler, F. Couch, 2010, PLoS Genetics.

Challenges in Interpreting Germline Mutations in BARD1 and ATM in Breast and Ovarian Cancer Patients

N. Tung, S. Balk, E. Hofstatter, 2017, The breast journal.

International Rates of Breast Reconstruction After Prophylactic Mastectomy in BRCA1 and BRCA2 Mutation Carriers

J. Lubiński, S. Neuhausen, N. Tung, 2013, Annals of Surgical Oncology.

Wild-Type BRCA1, but not Mutated BRCA1, Regulates the Expression of the Nuclear Form of β-Catenin

N. Tung, M. Sekine, H. Avraham, 2010, Molecular Cancer Research.

A prior diagnosis of breast cancer is a risk factor for breast cancer in BRCA1 and BRCA2 carriers.

W. Foulkes, S. Neuhausen, M. Robson, 2014, Current oncology.

Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.

O. Olopade, W. Foulkes, N. Tung, 2015, JAMA oncology.

Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial

E. Winer, R. Gelber, L. Trippa, 2022, NPJ breast cancer.

Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial.

M. Robson, Bing-he Xu, N. Tung, 2019, European journal of cancer.

Identiﬁcation of four novel susceptibility loci for oestrogen receptor negative breast cancer

Nussbaum, S. Cross, P. Fasching, 2016 .

Ophira M. GinsburgCharmaine Kim-SingWilliam D. Foulkes • Parviz GhadirianHenry T. LynchPing SunSteven A. Narod • Hereditary Breast Cancer Clinical Study Group

F. Couch, O. Olopade, B. Karlan, 2010 .

Smoking and the risk of breast cancer among carriers of BRCA mutations

D. Horsman, W. Foulkes, B. Weber, 2004, International journal of cancer.

Phenotypic characteristics associated with the APC gene I1307K mutation in Ashkenazi Jewish patients with colorectal polyps.

J. Garber, N. Tung, D. Schrag, 2000, JAMA.

The impact of oophorectomy on survival after breast cancer in BRCA1 and BRCA2 mutation carriers.

O. Olopade, W. Foulkes, N. Tung, 2014 .

Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.

R. Schilsky, J. Heymach, J. D. de Groot, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Should all BRCA1 mutation carriers with stage I breast cancer receive chemotherapy?

O. Olopade, W. Foulkes, K. Offit, 2013, Breast Cancer Research and Treatment.

Challenges in Interpreting TP53 Pathogenic Variants With a Low Minor Allele Frequency in Germline Genetic Testing: A Case Report of a Patient With Mosaic Li-Fraumeni Syndrome

N. Tung, Felipe Batalini, Ellie G. Peacock, 2020 .

Family communication and patient distress after germline genetic testing in individuals with pancreatic ductal adenocarcinoma

N. Tung, R. Brand, V. Speare, 2019, Cancer.

Prospective study of germline genetic testing in incident cases of pancreatic adenocarcinoma

N. Tung, A. Moser, R. Brand, 2018, Cancer.

Male breast cancer in BRCA1 and BRCA2 mutation carriers

R. Nussbaum, D. Steinemann, F. Couch, 2018 .

Abstract GS1-05: TBCRC 033: A randomized phase II study of adjuvant trastuzumab emtansine (T-DM1) vs paclitaxel (T) in combination with trastuzumab (H) for stage I HER2-positive breast cancer (BC) (ATEMPT)

E. Winer, L. Trippa, R. Bose, 2020 .

OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm).

M. Robson, Bing-he Xu, N. Tung, 2017 .

PARP inhibition in breast cancer: progress made and future hopes

J. Garber, N. Tung, 2022, NPJ breast cancer.

E. Winer, Minetta C. Liu, R. Bose, 2021, Breast Cancer Research and Treatment.

Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers

W. Chung, D. Steinemann, F. Couch, 2022, Communications Biology.

Overexpression of BLM promotes DNA damage and increased sensitivity to platinum salts in triple-negative breast and serous ovarian cancers

Z. Szallasi, M. Dreze, A. Richardson, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Coffee consumption and breast cancer risk among BRCA1 and BRCA2 mutation carriers

Jan Lubinski, Charis Eng, Ping Sun, 2006, International journal of cancer.

Genetic Counseling in Oncology—Reply

N. Tung, 2011 .

Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170

Nicholas A. Sinnott-Armstrong, Richard C. Sallari, S. Cross, 2016, Nature Genetics.

Germline mutations in CDH1 are infrequent in women with early-onset or familial lobular breast cancers

O. Olopade, M. Southey, P. Miron, 2010, Journal of Medical Genetics.

JMEDGENET79814 1..5

O. Olopade, M. Southey, P. Miron, 2022 .

Retinoblastoma protein expression and its predictors in triple-negative breast cancer

G. Freeman, S. Schnitt, J. Garber, 2020, npj Breast Cancer.

Adherence to National Comprehensive Cancer Network Guidelines for BRCA testing among high risk breast Cancer patients: a retrospective chart review study

N. Tung, M. Duh, R. Shenolikar, 2020, Hereditary Cancer in Clinical Practice.

Mammography screening and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a prospective study

P. Møller, W. Foulkes, J. Lubiński, 2014, Breast Cancer Research and Treatment.

c‐myc in Kaposi’s sarcoma: analyses by fluorescent in situ hybridization and immunohistochemistry

N. Tung, M. Mahalingam, S. Yang, 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.

Subgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD

M. Robson, Bing-he Xu, N. Tung, 2018 .

Reply to S.M. Sorscher and M.J. Hall et al.

J. Garber, N. Tung, 2016, Journal of Clinical Oncology.

Immediate breast reconstruction following mastectomy in pregnant women with breast cancer

J. Bellon, S. Troyan, N. Tung, 2016, Journal of surgical oncology.

Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022.

Elizabeth C. Randall, E. Winer, N. Ibrahim, 2020, Clinical breast cancer.

Does preventive oophorectomy increase the risk of depression in BRCA mutation carriers?

B. Karlan, W. Foulkes, J. Lubiński, 2020, Menopause.

Translational Breast Cancer Research Consortium 022: Pre- and Post-operative Neratinib for HER2-positive Breast Cancer Brain Metastases

Elizabeth C. Randall, E. Winer, N. Ibrahim, 2020 .

A randomized study of cash cards versus checks as clinician survey incentives

B. Karlan, N. Keating, K. Offit, 2020 .

TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases

E. Winer, N. Ibrahim, R. Gelman, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Weight Gain and the Risk of Ovarian Cancer in BRCA1 and BRCA2 Mutation Carriers

O. Olopade, B. Karlan, P. Møller, 2021, Cancer Epidemiology, Biomarkers & Prevention.

Shared heritability and functional enrichment across six solid cancers

K. D. Sørensen, Stephanie A. Bien, Ali Amin Al Olama, 2019, Nature Communications.

Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers

P. Lønning, S. Knappskog, D. Solit, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers

W. Foulkes, L. Salmena, J. Lubiński, 2012, Breast Cancer Research.

Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors.

M. Regan, N. Tung, R. Duda, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer (OlympiAD): Efficacy in patients with visceral metastases.

M. Robson, Bing-he Xu, N. Tung, 2018 .

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

M. Robson, Bing-he Xu, N. Tung, 2017, The New England journal of medicine.

Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)

Päivi Heikkilä, Mads Thomassen, Stephen Fox, 2011, Cancer Epidemiology, Biomarkers & Prevention.

Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness.

Stefania Tommasi, Laura Cortesi, Mads Thomassen, 2019, Cancer research.

Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation.

F. Couch, O. Olopade, B. Karlan, 2020, Gynecologic oncology.

Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants

D. Steinemann, F. Couch, B. Bonanni, 2020, Genetics in Medicine.

Medical Management of newly diagnosed breast cancer in a BRCA1/2 mutation carrier

N. Tung, N. Desai, 2020, The breast journal.

Reply to S. Takamizawa et al.

J. Garber, N. Tung, M. Hacker, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term outcomes following a diagnosis of ovarian cancer at the time of preventive oophorectomy among BRCA1 and BRCA2 mutation carriers

B. Karlan, P. Møller, W. Foulkes, 2020, International Journal of Gynecological Cancer.

Patterns of recurrence and metastasis in BRCA1/BRCA2‐associated breast cancers

W. Barry, J. Garber, N. Lin, 2019, Cancer.

Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses

Jack A. Taylor, W. Chung, S. Cross, 2019, bioRxiv.

BRCA1/2 testing: therapeutic implications for breast cancer management

J. Garber, N. Tung, 2018, British Journal of Cancer.

Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer

Michael Jones, Peter Kraft, Arnaud Droit, 2017, Nature Genetics.

Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast–ovarian cancer susceptibility locus

A. Whittemore, L. Kiemeney, S. Cross, 2016, Nature Communications.

Prevalence and predictors of androgen receptor and programmed death-ligand 1 in BRCA1-associated and sporadic triple-negative breast cancer

G. Freeman, S. Schnitt, J. Garber, 2016, npj Breast Cancer.

Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2

R. Nussbaum, D. Steinemann, F. Couch, 2016, Breast Cancer Research.

Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers

R. Nussbaum, D. Steinemann, V. Pankratz, 2014, Breast Cancer Research.

Outcome of triple negative breast cancer: comparison of sporadic and BRCA1-associated cancers

S. Schnitt, J. Garber, N. Tung, 2014, Breast Cancer Research and Treatment.

Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers

S. Gautam, A. Richardson, D. Sgroi, 2010, Breast Cancer Research.

A Comparison of Bilateral Breast Cancers in BRCA Carriers

O. Olopade, P. Møller, W. Foulkes, 2005, Cancer Epidemiology Biomarkers & Prevention.

Estrogen Receptor Status in BRCA1- and BRCA2-Related Breast Cancer

O. Olopade, L. Bégin, W. Foulkes, 2004, Clinical Cancer Research.

Oncotype DX® Recurrence Score as a Predictor of Response to Neoadjuvant Chemotherapy

N. Tung, T. James, Luis A. Riba, 2018, Annals of Surgical Oncology.

Transcriptome ‐ wide association study of breast cancer risk by estrogen ‐ receptor status

Jack A. Taylor, W. Chung, S. Cross, 2020 .

Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy

J. Baselga, J. Garber, N. Tung, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genetic predisposition directs breast cancer phenotype by dictating progenitor cell fate.

E. Lander, Piyush B. Gupta, S. Schnitt, 2011, Cell stem cell.

Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next‐generation sequencing with a 25‐gene panel

Karla Bowles, Satish Bhatnagar, J. Garber, 2015, Cancer.

Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer

Z. Szallasi, G. Mills, E. Winer, 2016, Clinical Cancer Research.

Homologous Recombination De fi ciency ( HRD ) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer

Z. Szallasi, G. Mills, E. Winer, 2016 .

Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents.

Z. Szallasi, A. Eklund, Qiyuan Li, 2012, Cancer discovery.

Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women

Olufunmilayo I. Olopade, Mads Thomassen, Dieter Niederacher, 2016, Breast Cancer Research.

The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers

P. Møller, W. Foulkes, J. Iqbal, 2012, British Journal of Cancer.

Should We Offer Medication to Reduce Breast Cancer Risk?

N. Tung, M. Schonberg, R. Burns, 2016, Annals of Internal Medicine.

Incidence and Prevalence of Intraductal Papillary Mucinous Neoplasms in Individuals With BRCA1 and BRCA2 Pathogenic Variant

N. Tung, M. Bilal, V. Wadhwa, 2022, Journal of clinical gastroenterology.

Cellular myosin heavy chain in human leukocytes: isolation of 5' cDNA clones, characterization of the protein, chromosomal localization, and upregulation during myeloid differentiation

M. L. Beau, D. Tenen, N. Tung, 1991 .

TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial).

E. Winer, S. Schnitt, J. Garber, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes

Jane E. Carpenter, Jack A. Taylor, W. Chung, 2019, Nature Genetics.

BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers.

Dong Liang, Patrick Neven, Harvey Risch, 2016, Journal of the National Cancer Institute.

A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk.

Harvey Risch, Yian A Chen, Mads Thomassen, 2018, Cancer research.

University of Groningen Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk Couch,

F. Couch, B. Bonanni, O. Olopade, 2013 .

TBCRC 048: A phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes (Olaparib Expanded).

E. Winer, J. Garber, A. Wolff, 2020 .

Chronic Pancreatitis–Like Change in BRCA2 Mutation Carriers

T. Berzin, N. Tung, D. Pleskow, 2017, Pancreas.

Common Genetic Variants and Modification of Penetrance of BRCA2-Associated Breast Cancer

M. Daly, D. Altshuler, F. Couch, 2010, PLoS genetics.

Cellular myosin heavy chain in human leukocytes: isolation of 5' cDNA clones, characterization of the protein, chromosomal localization, and upregulation during myeloid differentiation.

D. Tenen, M. L. Le Beau, N. Tung, 1991, Blood.

Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers

W. Chung, D. Steinemann, F. Couch, 2019, British Journal of Cancer.

Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer

Sarah A. Boswell, P. Sorger, Jia-Ren Lin, 2020, Nature Cancer.

PARP inhibition in breast cancer: progress made and future hopes

J. Garber, N. Tung, 2022, npj Breast Cancer.

An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriers

B. Karlan, S. Buys, Sung-Won Kim, 2016, Breast Cancer Research and Treatment.

Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer.

Mads Thomassen, Nina Ditsch, Muhammad Usman Rashid, 2015, JAMA.

Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer

Jane E. Carpenter, Jack A. Taylor, W. Chung, 2019, Nature Communications.

Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study.

Katherine M. Tucker, W. Chung, R. Nussbaum, 2018, Journal of the National Cancer Institute.

The incidence of leukaemia in women with BRCA1 and BRCA2 mutations: an International Prospective Cohort Study

Stephanie A Cohen, F. Couch, O. Olopade, 2016, British Journal of Cancer.

Incidence of colorectal cancer in BRCA1 and BRCA2 mutation carriers: results from a follow-up study

Charis Eng, Fergus Couch, Kevin Sweet, 2013, British Journal of Cancer.

Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers

Joshua M. Korn, M. Daly, D. Altshuler, 2011, Human Genetics.

Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer

Jane E. Carpenter, A. Whittemore, W. Chung, 2016, Nature Communications.

Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.

Rosalind Eeles, Susan L Neuhausen, Fergus J Couch, 2010, JAMA.

Polygenic risk modeling for prediction of epithelial ovarian cancer risk

A. Whittemore, W. Chung, L. Kiemeney, 2022, European Journal of Human Genetics.

Phase II trial of veliparib and temozolomide in metastatic breast cancer patients with and without BRCA1/2 mutations

E. Winer, R. Gelman, J. Garber, 2021, Breast Cancer Research and Treatment.

Dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2/neu-positive breast cancer is not feasible due to excessive diarrhea: updated results.

D. Lake, C. Hudis, L. Norton, 2009 .

A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers

Jane E. Carpenter, Jack A. Taylor, W. Chung, 2021, Nature Communications.

No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.

Sandra L. Halverson, A. Whittemore, L. Kiemeney, 2016, Gynecologic oncology.

Association of Tumor-Infiltrating Lymphocytes with Homologous Recombination Deficiency and BRCA1/2 Status in Patients with Early Triple-Negative Breast Cancer: A Pooled Analysis

A. Richardson, W. Gradishar, J. Garber, 2019, Clinical Cancer Research.

Tumor-infiltrating lymphocytes and response to platinum in triple-negative breast cancer.

E. Winer, N. Tung, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriers

S. Schnitt, J. Garber, N. Tung, 2011, Cancer.

Pathology of Breast andOvarian Cancers among BRCA 1 and BRCA 2 Mutation Carriers : Results from the Consortium of Investigators of Modi fi ers of BRCA 1 / 2 ( CIMBA )

R. Nussbaum, V. Pankratz, F. Couch, 2011 .

Management of women with BRCA mutations: a 41-year-old woman with a BRCA mutation and a recent history of breast cancer.

N. Tung, 2011, JAMA.

Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: An update

O. Olopade, W. Foulkes, K. Offit, 2006, International journal of cancer.

Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.

Ellen Warner, Ping Sun, Olufunmilayo I Olopade, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer

Lara E Sucheston-Campbell, Simon G. Coetzee, Dennis J. Hazelett, 2017, Nature Genetics.

Pathologic Features and Immunophenotype of Estrogen Receptor–positive Breast Cancers in BRCA1 Mutation Carriers

R. West, S. Schnitt, J. Garber, 2012, The American journal of surgical pathology.

Abstract P3-06-11: Homologous recombination deficiency (HRD) assay predicts response to cisplatin neoadjuvant chemotherapy in patients with triple negative breast cancer

Z. Szallasi, E. Winer, A. Richardson, 2015 .

P3-16-05: A Phase II Trial Expansion Cohort of the PARP Inhibitor Veliparib (ABT888) and Temozolomide in BRCA1/2 Associated Metastatic Breast Cancer.

E. Winer, R. Gelman, J. Garber, 2011 .

The predictive ability of the 313 variant–based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant

W. Chung, F. Couch, O. Olopade, 2021, Genetics in Medicine.

ManagementofWomenWith BRCA Mutations A 41-Year-Old Woman With a BRCA Mutation and a Recent History of Breast Cancer

N. Tung, 2011 .

Modification of BRCA1-Associated Breast and Ovarian Cancer Risk by BRCA1-Interacting Genes.

F. Couch, O. Olopade, T. Rebbeck, 2011, Cancer research.

Li-Fraumeni syndrome: not a straightforward diagnosis anymore—the interpretation of pathogenic variants of low allele frequency and the differences between germline PVs, mosaicism, and clonal hematopoiesis

J. Garber, N. Tung, J. Weitzel, 2019, Breast Cancer Research.

Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriers

O. Olopade, B. Karlan, P. Møller, 2006, Breast Cancer Research.

A Nonsynonymous Polymorphism in IRS1 Modifies Risk of Developing Breast and Ovarian Cancers in BRCA1 and Ovarian Cancer in BRCA2 Mutation Carriers

W. Chung, V. Pankratz, F. Couch, 2012, Cancer Epidemiology, Biomarkers & Prevention.

Genetic Variation in IGF 2 and HTRA 1 and Breast Cancer Risk among BRCA 1 and BRCA 2 Carriers

F. Couch, O. Olopade, T. Rebbeck, 2011 .

Common Genetic Variants and Modification of Penetrance of BRCA2-Associated Breast Cancer

Joshua M. Korn, Debra, M. Daly, 2010, PLoS genetics.

International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers

Jan Lubinski, Fergus Couch, Ping Sun, 2008, International journal of cancer.

When Should Tumor Genomic Profiling Prompt Consideration of Germline Testing?

S. Cannistra, N. Tung, K. DeLeonardis, 2019, Journal of oncology practice.

Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.

Yuya Kobayashi, James M Ford, Stephen E Lincoln, 2015, JAMA oncology.

Comparison of up-front cash cards and checks as incentives for participation in a clinician survey: a study within a trial

B. Karlan, N. Keating, K. Offit, 2020, BMC Medical Research Methodology.

The BRCA founder outreach study: Initial results of a digital health model.

Jeffrey S. Levin, B. Karlan, K. Offit, 2020 .

Effect of Prior Bilateral Oophorectomy on the Presentation of Breast Cancer in BRCA1 and BRCA2 Mutation Carriers

O. Olopade, W. Foulkes, B. Weber, 2005, Hereditary cancer in clinical practice.

Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers.

F. Couch, O. Olopade, T. Rebbeck, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer.

D. Fishman, B. Karlan, J. Brunet, 2000, American journal of human genetics.

The risks of cancer in older women with BRCA pathogenic variants: How far have we come?

F. Couch, O. Olopade, P. Møller, 2022, Cancer.

Clinical Actionability ofMultigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment

S. Lincoln, N. Tung, A. Kurian, 2015 .

Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus

Jane E. Carpenter, A. Whittemore, S. Cross, 2016, Breast Cancer Research.

Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case–control study

B. Karlan, P. Møller, W. Foulkes, 2016, Breast Cancer Research and Treatment.

A phase II study of efficacy, toxicity, and the potential impact of genomic alterations on response to eribulin mesylate in combination with trastuzumab and pertuzumab in women with human epidermal growth factor receptor 2 (HER2)+ metastatic breast cancer

N. Lin, N. Tung, N. Wagle, 2021, Breast Cancer Research and Treatment.

Early results from the BRCA Founder Outreach (BFOR) Study: Population genetic screening using a medical model.

B. Karlan, K. Offit, K. Nathanson, 2019, Journal of Clinical Oncology.

A Pre-Test-Post-Test Trial of a Breast Cancer Risk Report for Women in Their 40s.

Roger B. Davis, Tejas Mehta, N. Tung, 2020, American journal of preventive medicine.

International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation

B. Karlan, P. Møller, W. Meschino, 2019, British Journal of Cancer.

Clinical characteristics and outcomes of BRCA-associated ovarian cancer: genotype and survival.

J. Garber, S. Neuhausen, N. Tung, 2012, Cancer genetics.

Association of breast cancer risk in BRCA 1 and BRCA 2 mutation carriers with genetic variants showing differential allelic expression

R. Nussbaum, F. Couch, O. Olopade, 2016 .

Breast cancer risk variants at 6 q 25 display different phenotype associations and regulate ESR 1 , RMND 1 and CCDC 170

Wei Zheng, Mads Thomassen, Nicholas A. Sinnott-Armstrong, 2016 .

An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers

W. Chung, R. Nussbaum, D. Steinemann, 2015, Breast Cancer Research.

Title Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA 1 and BRCA 2 mutation carriers

R. Nussbaum, D. Steinemann, V. Pankratz, 2015 .

phylogenetic approach identified mitochondrial haplogroup T 1 a 1 as inversely associated with breast cancer risk in BRCA 2 mutation carriers

W. Chung, D. Steinemann, V. Pankratz, 2015 .

Abstract PD4-03: OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

M. Robson, Bing-he Xu, N. Tung, 2020 .

PALB2 mutations in familial breast and pancreatic cancer

P. Miron, K. Nathanson, J. Garber, 2011, Familial Cancer.

How to manage patients with moderate-risk germline mutations.

N. Tung, 2018, Clinical advances in hematology & oncology : H&O.

Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0

E. Winer, J. Foster, N. Tung, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

R. Gelber, L. Trippa, Minetta C. Liu, 2022, npj Breast Cancer.

Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial

E. Winer, R. Gelber, L. Trippa, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Wild-Type BRCA1, but not Mutated BRCA1, Regulates the Expression of the Nuclear Form of β-Catenin

N. Tung, M. Sekine, H. Avraham, 2010, Molecular Cancer Research.

The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer

W. Chung, M. Beckmann, P. Fasching, 2019, npj Breast Cancer.

Challenges to the development of new agents for molecularly defined patient subsets: lessons from BRCA1/2-associated breast cancer.

A. Tutt, N. Loman, J. Garber, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patient perspectives on chemotherapy de‐escalation in breast cancer

A. Wolff, A. DeMichele, N. Tung, 2021, Cancer medicine.

Contemporary multidisciplinary treatment of pregnancy-associated breast cancer

N. Tung, S. Gelber, A. Partridge, 2013, SpringerPlus.

Disruption of the expected positive correlation between breast tumor size and lymph node status in BRCA1‐related breast carcinoma

L. Bégin, P. Chappuis, W. Foulkes, 2003, Cancer.

A phase 1b study of safety and immune response to PVX-410 vaccine alone and in combination with durvalumab (MEDI4736) in HLA-A2+ patients following adjuvant therapy for stage 2/3 triple negative breast cancer.

W. Barry, S. Adams, N. Tung, 2017 .

TBCRC 030: A randomized phase II study of preoperative cisplatin versus paclitaxel in TNBC—Evaluating the homologous recombination deficiency (HRD) biomarker.

C. Perou, E. Winer, A. Richardson, 2019, Journal of Clinical Oncology.

Alcohol consumption and the risk of breast cancer among BRCA1 and BRCA2 mutation carriers.

Daniel Krewski, Susan L Neuhausen, Jan Lubinski, 2010, Breast.

Treatment of infertility does not increase the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation.

B. Karlan, P. Møller, J. Lubiński, 2016, Fertility and sterility.

Frequency of premature menopause in women who carry a BRCA1 or BRCA2 mutation.

B. Karlan, W. Foulkes, S. Neuhausen, 2013, Fertility and sterility.

Retinoblastoma (Rb) protein expression in triple-negative breast cancer.

S. Schnitt, J. Garber, N. Tung, 2017 .

The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

Andrew H. Beck, Clare C. Yu, M. N. Vidya, 2021, npj Breast Cancer.

Modification of BRCA 1-Associated Breast and Ovarian Cancer Risk by BRCA 1-Interacting Genes

F. Couch, O. Olopade, T. Rebbeck, 2011 .

Phase 2 study of response-guided neoadjuvant sacituzumab govitecan (IMMU-132) in patients with localized triple-negative breast cancer: Results from the NeoSTAR trial.

L. Trippa, A. Bardia, N. Tung, 2022, Journal of Clinical Oncology.

Factors associated with use of hormone therapy after preventive oophorectomy in BRCA mutation carriers

B. Karlan, N. Tung, S. Narod, 2020, Menopause.

Modification of ovarian cancer risk by BRCA1/2-interacting genes in a multicenter cohort of BRCA1/2 mutation carriers.

Nandita Mitra, Georgia Chenevix-Trench, Susan L Neuhausen, 2009, Cancer research.

Chek2 DNA damage response pathway and inherited breast cancer risk.

N. Tung, D. Silver, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials

Jacqueline A. Hall, Sarah N. Dudgeon, A. Gown, 2020, npj Breast Cancer.

A011801 (CompassHER2 RD): Postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer.

L. Carey, W. Symmans, M. Goetz, 2021 .

The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: an international prospective cohort study.

B. Karlan, P. Møller, W. Foulkes, 2013, Gynecologic oncology.

Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers

O. Olopade, P. Møller, W. Foulkes, 2014, Breast Cancer Research and Treatment.

Refining Risk Assessment in Women With Benign Breast Disease: An Ongoing Dilemma.

S. Schnitt, M. Morrow, N. Tung, 2017, Journal of the National Cancer Institute.

A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer

E. Winer, N. Tung, E. Mittendorf, 2022, NPJ breast cancer.

Olaparib efficacy in patients with germline BRCA‐mutated, HER2‐negative metastatic breast cancer: Subgroup analyses from the phase III OlympiAD trial

M. Robson, Bing-he Xu, N. Tung, 2023, International journal of cancer.

International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation

B. Karlan, P. Møller, W. Meschino, 2019, British Journal of Cancer.

Sentinel Lymph Node Biopsy in Pregnant Women with Breast Cancer

S. Troyan, N. Tung, L. Schapira, 2014, Annals of Surgical Oncology.

Adjuvant PARP Inhibitors in Patients With High-Risk Early-Stage HER2-Negative Breast Cancer and Germline BRCA Mutations: ASCO Hereditary Breast Cancer Guideline Rapid Recommendation Update.

M. Somerfield, N. Tung, D. Zakalik, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Variation in Breast Cancer Risk Model Estimates Among Women in Their 40s Seen in Primary Care.

Roger B. Davis, Tejas Mehta, N. Tung, 2022, Journal of women's health.

Recommendation Recall and Satisfaction After Attending Breast/Ovarian Cancer Risk Counseling

N. Tung, R. Duda, L. Hoke, 2007, Journal of Genetic Counseling.

Breast cancer screening in the era of density notification legislation: summary of 2014 Massachusetts experience and suggestion of an evidence-based management algorithm by multi-disciplinary expert panel

Phoebe E. Freer, R. Birdwell, S. Troyan, 2015, Breast Cancer Research and Treatment.

Outcomes after treatment of breast cancer during pregnancy including taxanes and/or granulocyte colony-stimulating factor use: findings from a multi-institutional retrospective analysis

N. Lin, N. Tung, B. Moy, 2022, Breast Cancer Research and Treatment.

Adjuvant Olaparib for Germline BRCA Carriers With HER2-Negative Early Breast Cancer: Evidence and Controversies

J. Garber, N. Lin, G. Curigliano, 2023, The oncologist.

Survival from breast cancer in women with a BRCA2 mutation by treatment

F. Couch, P. Møller, W. Foulkes, 2021, British Journal of Cancer.

Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer.

C. Perou, L. Carey, A. Wolff, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

Abstract OT2-18-01: Harnessing olaparib, palbociclib, and endocrine therapy (HOPE): Phase I/II trial of olaparib, palbociclib and fulvestrant in patients with BRCA1/2-associated, hormone receptor-positive, HER2-negative metastatic breast cancer

K. Nathanson, M. Robson, N. Tung, 2022, Cancer Research.

Assessment of the HER2DX Assay in Patients With ERBB2-Positive Breast Cancer Treated With Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab.

C. Perou, J. Parker, N. Tung, 2023, JAMA oncology.

J. Garber, N. Tung, J. Weitzel, 2019, Breast Cancer Research.

TBCRC 022: Phase II trial of neratinib + capecitabine for patients (Pts) with human epidermal growth factor receptor 2 (HER2+) breast cancer brain metastases (BCBM).

E. Winer, Minetta C. Liu, R. Gelman, 2017 .

Tamoxifen and the risk of breast cancer in women with a BRCA1 or BRCA2 mutation

F. Couch, O. Olopade, P. Møller, 2023, Breast Cancer Research and Treatment.

Oncologist-Reported Barriers and Facilitators to Enrolling Patients in Optimization Trials That Test Less Intense Cancer Treatment

N. Tung, L. Wagner, G. Rocque, 2022, JCO oncology practice.

Adjuvant palbociclib (P) plus endocrine therapy (ET) for hormone receptor positive (HR+) breast cancer: A phase II feasibility study.

E. Winer, W. Barry, H. Burstein, 2014 .

Rapid progression of prostate cancer in men with a BRCA2 mutation

P Ghadirian, F. Couch, D. Horsman, 2008, British Journal of Cancer.

BRCA1/2 testing: therapeutic implications for breast cancer management

J. Garber, N. Tung, 2018, British Journal of Cancer.

Potential pathogenic germline variant reporting from tumor comprehensive genomic profiling complements classic approaches to germline testing

Rachel B. Keller, N. Tung, H. Tukachinsky, 2023, NPJ precision oncology.

Abstract P3-09-15: A phase 1b study of PVX-410 (PVX) vaccine plus durvalumab (DUR) as adjuvant therapy in HLA-A2+ early stage triple negative breast cancer (eTNBC) to assess safety and immune response

L. Trippa, W. Barry, S. Adams, 2020 .

Surgical Complications and the Use of Neoadjuvant Bevacizumab.

Barbara L. Smith, S. Troyan, R. Gelman, 2009 .

A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer

N. Tung, E. Mittendorf, T. King, 2022, npj Breast Cancer.

Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus

Jane E. Carpenter, A. Whittemore, S. Cross, 2016, Breast Cancer Research.

The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer

Jane E. Carpenter, W. Chung, M. Beckmann, 2019, npj Breast Cancer.

Common Genetic Variation at BARD1 Is Not Associated with Breast Cancer Risk in BRCA1 or BRCA2 Mutation Carriers

F. Couch, O. Olopade, T. Rebbeck, 2011, Cancer Epidemiology, Biomarkers & Prevention.

Null Results in Brief Common Genetic Variation at BARD 1 Is Not Associated with Breast Cancer Risk in BRCA 1 or BRCA 2 Mutation Carriers

O. Olopade, T. Rebbeck, R. Eeles, 2011 .

Phase I, open-label study of olaparib plus cisplatin in patients with advanced solid tumors.

E. Winer, J. Baselga, J. Garber, 2012 .

Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer.

L. Carey, W. Symmans, M. Goetz, 2021, Future oncology.

Analysis of real-world (RW) data for metastatic breast cancer (mBC) patients (pts) with somatic BRCA1/2 (sBRCA) or other homologous recombination (HR)-pathway gene mutations (muts) treated with PARP inhibitors (PARPi).

E. Sokol, J. Garber, G. Frampton, 2021 .

Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus

A. Whittemore, S. Cross, R. Nussbaum, 2016, Breast Cancer Research.

Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation.

B. Karlan, P. Møller, W. Foulkes, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer.

E. Winer, J. Garber, N. Lin, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.

S. Lincoln, N. Tung, A. Kurian, 2015, JAMA oncology.

Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents.

Z. Szallasi, A. Eklund, N. Tung, 2012, Cancer Discovery.

No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.

Sandra L. Halverson, A. Whittemore, L. Kiemeney, 2016, Gynecologic oncology.

Identification of six new susceptibility loci for invasive epithelial ovarian cancer

Yurii B. Shvetsov, Simon G. Coetzee, Dennis J. Hazelett, 2014, Nature Genetics.

The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: an international prospective cohort study.

B. Karlan, P. Møller, W. Foulkes, 2013, Gynecologic oncology.

Anthropometric Measures and Risk of Ovarian Cancer Among BRCA1 and BRCA2 Mutation Carriers

B. Karlan, W. Foulkes, J. Lubiński, 2012, Obesity.

A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk.

L. Kiemeney, P. Fasching, R. Nussbaum, 2018, Cancer research.

Altered proliferation and differentiation properties of primary mammary epithelial cells from BRCA1 mutation carriers.

Bernard T. Lee, S. Troyan, N. Tung, 2009, Cancer research.

Treatment of infertility does not increase the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation.

B. Karlan, P. Møller, J. Lubiński, 2016, Fertility and sterility.

Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.

F. Couch, O. Olopade, J. Klijn, 2002, Journal of the National Cancer Institute.

Modification of ovarian cancer risk by BRCA1/2-interacting genes in a multicenter cohort of BRCA1/2 mutation carriers.

F. Couch, O. Olopade, T. Rebbeck, 2009, Cancer research.

Management of women with BRCA mutations: a 41-year-old woman with a BRCA mutation and a recent history of breast cancer.

N. Tung, 2011, JAMA.

Second primary ipsilateral breast cancer with contralateral axillary involvement: a case report and literature review.

N. Tung, Elizabeth M. Gaughan, C. Herold, 2011, Clinical breast cancer.

Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer.

A. Whittemore, F. Couch, B. Bonanni, 2015 .

Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypes

A. Richardson, A. Gutin, M. Goetz, 2023, Breast Cancer Research and Treatment.

Intrinsic molecular subtypes of breast cancers categorized as HER2-positive using an alternative chromosome 17 probe assay

C. Perou, J. Auman, S. Schnitt, 2018, Breast Cancer Research.

Translational Breast Cancer Research Consortium 022: Pre- and Post-operative Neratinib for HER2-positive Breast Cancer Brain Metastases

Elizabeth C. Randall, E. Winer, N. Ibrahim, 2020 .

Transcriptome-wide association study of breast cancer risk by estrogen-receptor status

Jack A. Taylor, S. Cross, C. Vachon, 2020, Genetic epidemiology.

Is hormone replacement therapy (HRT) following risk-reducing salpingo-oophorectomy (RRSO) in BRCA1 (B1)- and BRCA2 (B2)-mutation carriers associated with an increased risk of breast cancer?

F. Couch, T. Rebbeck, R. Eeles, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.